Frequent methylation of RASSF1 and RARB in urine sediments from patients with early stage prostate cancer.

BACKGROUND. Prostate cancer (PCa) is the second most prevalent malignancy among males, characterized by high mortality rates. Aberrant DNA methylation in promoters of tumor suppressor genes is an early and frequent event during prostate carcinogenesis. Modern techniques allow a sensitive detection of DNA methylation biomarkers in bodily fluids from cancer patients offering a noninvasive tool for PCa monitoring. Our study aimed at the analysis of DNA methylation in urine sediments from PCa patients for the selection of most informative noninvasive biomarkers. MATERIAL AND METHODS. Real-time methylation-specific polymerase chain reaction was used for the detection of methylated RASSF1, RARB, and GSTP1 genes in catheterized urine specimens from 34 patients with biopsy-proven early or medium stage PCa. RESULTS. At least one gene was methylated in urine sediments from 28 cases with PCa, with a sensitivity of the test reaching 82%. RASSF1 was methylated in 71% (24 of 34), RARB in 44% (15 of 34), and GSTP1 in 3% (1 of 34) of the specimens. High level of methylation (≥50%) in RARB and RASSF1 genes was detected in 40% and 20% of cases, respectively. A significant association was observed between high level of RARB methylation and Gleason score (P=0.01), while methylation of at least one gene occurred more frequently in urine DNA of older patients (P=0.02). CONCLUSIONS. Results of our study show a high sensitivity of DNA methylation biomarkers, especially RASSF1 and RARB, for the early and noninvasive detection of PCa.

[1]  J. Ellinger,et al.  The role of cell-free circulating DNA in the diagnosis and prognosis of prostate cancer. , 2011, Urologic oncology.

[2]  V. Apprey,et al.  Identification of Differentially Methylated Genes in Normal Prostate Tissues from African American and Caucasian Men , 2010, Clinical Cancer Research.

[3]  O. Cussenot,et al.  Methylated genes as potential biomarkers in prostate cancer , 2010, BJU international.

[4]  Hafiz Ahmed.  Promoter Methylation in Prostate Cancer and its Application for the Early Detection of Prostate Cancer Using Serum and Urine Samples , 2010, Biomarkers in cancer.

[5]  J. Serth,et al.  DNA methylation biomarkers of prostate cancer: Confirmation of candidates and evidence urine is the most sensitive body fluid for non‐invasive detection , 2009, The Prostate.

[6]  W. Schulz,et al.  Epigenetic mechanisms in the biology of prostate cancer. , 2009, Seminars in cancer biology.

[7]  T. Dorff,et al.  Multimarker circulating DNA assay for assessing blood of prostate cancer patients. , 2009, Clinical chemistry.

[8]  K. Husgafvel‐Pursiainen,et al.  Promoter Hypermethylation in Tumour Suppressor Genes Shows Association with Stage, Grade and Invasiveness of Bladder Cancer , 2008, Oncology.

[9]  A. Mazumder,et al.  Development of a multiplexed urine assay for prostate cancer diagnosis. , 2008, Clinical chemistry.

[10]  J. Kurtinaitis,et al.  Cancer mortality differences among urban and rural residents in Lithuania , 2008, BMC public health.

[11]  K. O’Reilly,et al.  The usefulness of the detection of GSTP1 methylation in urine as a biomarker in the diagnosis of prostate cancer. , 2008, The Journal of urology.

[12]  Ishtiaq Rehman,et al.  Molecular Detection of Localized Prostate Cancer Using Quantitative Methylation-Specific PCR on Urinary Cells Obtained Following Prostate Massage , 2007, Clinical Cancer Research.

[13]  R. Henrique,et al.  Epigenetic Markers for Molecular Detection of Prostate Cancer , 2007, Disease markers.

[14]  D. Chan,et al.  High concordance of gene methylation in post-digital rectal examination and post-biopsy urine samples for prostate cancer detection. , 2006, The Journal of urology.

[15]  M. Hoque,et al.  Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  A. Wellmann,et al.  Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  C. Rogers,et al.  Molecular profiling and classification of sporadic renal cell carcinoma by quantitative methylation analysis. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  M. Hoque,et al.  Quantitative RARbeta2 hypermethylation: a promising prostate cancer marker. , 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  Rui Henrique,et al.  Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. , 2002, Urology.

[20]  K. Miller,et al.  DNA‐Based Detection of Prostate Cancer in Blood, Urine, and Ejaculates , 2001, Annals of the New York Academy of Sciences.

[21]  J. Herman,et al.  Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  K. Miller,et al.  Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. , 2000, Cancer research.

[23]  E. Crawford,et al.  Comparison of telomerase activity and GSTP1 promoter methylation in ejaculate as potential screening tests for prostate cancer. , 2000, Molecular and cellular probes.